Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Novacyt ( (FR:ALNOV) ) has issued an update.
Novacyt S.A. has announced that its non-trading subsidiary, Lab 21 Healthcare Ltd, faces health and safety charges following an investigation by the Health and Safety Executive. These charges pertain to a facility previously operated by Lab 21 in Axminster, Devon, which was acquired from Omega Diagnostics Ltd in 2018 and no longer contributes to Novacyt’s current operations. An initial court hearing is scheduled for March 2025, with further announcements to follow, highlighting potential legal and operational implications for the company.
More about Novacyt
Novacyt is an international molecular diagnostics company that provides a wide range of integrated technologies and services. The company focuses on genomic medicine, developing and commercializing molecular assays and instrumentation for human health, animal health, and environmental sectors. Their operations are divided into clinical, instrumentation, and research use only segments, offering products from reproductive health diagnostics to DNA sample preparation platforms. Novacyt is headquartered in Le Vésinet, France, and maintains a global commercial presence across more than 65 countries.
YTD Price Performance: 9.98%
Average Trading Volume: 418
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $48.35M
See more data about ALNOV stock on TipRanks’ Stock Analysis page.
